Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Metastatic Pancreatic Neuroendocrine Tumor
Interventions
DRUG

Fulvestrant

"Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses."

DRUG

177Lu-DOTATATE

"Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles."

Trial Locations (1)

60637

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER